WW International, Inc. (NASDAQ: WW) has added Novo Nordisk’s Ozempic® pill (semaglutide) to its Med+ program, giving members a once‑daily oral GLP‑1 option for type 2 diabetes. The move expands the company’s portfolio of oral GLP‑1 treatments and reinforces its strategy to combine prescription medication with behavioral coaching and community support.
Members who qualify for Med+ will receive the pill along with a team of board‑certified clinicians, insurance‑utilization support, and a diabetes‑specific nutrition and coaching plan. The program also offers a blood‑sugar tracker to monitor patterns and changes over time, helping patients integrate the medication into daily life.
The addition comes as the Med+ segment grew 32% year‑over‑year in Q4 2025, with clinical subscribers reaching 130,000 and clinical ARPU more than four times the behavioral ARPU. By adding Ozempic® pill, WW aims to capture a larger share of the rapidly expanding GLP‑1 market and generate higher‑margin revenue that will help offset the decline in its traditional behavioral business.
Tara Comonte, CEO, said, 'Our industry is undergoing a profound transformation driven by GLP‑1 medications, and Weight Watchers is evolving alongside it.' She added, 'Our strategy is rooted in combining access to GLP‑1 medications with the behavioral support and community that have defined Weight Watchers for decades. As research continues to highlight the importance of pairing medication with structured support, this comprehensive weight health platform represents our long‑term competitive advantage.'
Jon Volkmann, Chief Operations Officer, noted, 'With the addition of Ozempic pill to our formulary, Weight Watchers Med+ is giving eligible members access to another FDA‑approved semaglutide option, supported by clinicians and a care team who can help them navigate insurance and by a broader program designed to support diabetes care in everyday life.'
The move positions WW against a competitive landscape dominated by Novo Nordisk and Eli Lilly, while differentiating the company from pure‑play digital health apps and pharma‑driven clinics. WW’s 2026 guidance projects revenue of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million, with the higher‑margin Med+ segment expected to lift overall profitability as the company continues to reduce debt and address the decline in its legacy behavioral subscription model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.